This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “Company,” together with its subsidiaries, the “Group”) on a voluntary basis to inform shareholders and potential inve

ImmuneOnco is pleased to announce that Dr. Weihai He (“Dr. He”) was appointed as a Chief Business Officer of the Group with effect from May 5, 2025. Dr. He is based in the United States and reports directly to Dr. Tian Wenzhi, the founder, Chairman of the Board, Chief Executive Officer and Chief Scientific Officer of the Company.

The National Medical Products Administration of the People’s Republic of China (the “NMPA”) Has Accepted the Group’s Application for a Clinical Trial of IMC-003/IMM72 for the Treatment of Pulmonary Arterial Hypertension (PAH)

The board (the “Board”) of directors (“Directors”, and each a “Director”) of the Company is pleased to announce that the Group has received approval from the National Medical Products Administration of the People’s Republic of China (the “NMPA”) for a clinical trial of IMM01 (Timdarpacept) in combination with IMM2510 (palverafusp α) and with or without chemotherapy, for the treatment of advanced malignant tumors.

On January 13, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Stock Code: 01541.HK) announced that the Phase Ib/II clinical trial of its PD-L1xVEGF bispecific antibody IMM2510 combined with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC) has completed the enrollment of its first patient. This marks another significant milestone in the rapid clinical advancement of IMM2510.